Save information for later
Sign Up

Learn About Von Hippel-Lindau (VHL) Syndrome

What is the definition of Von Hippel-Lindau (VHL) Syndrome?

Von Hippel-Lindau syndrome is an inherited disorder characterized by the formation of tumors and fluid-filled sacs (cysts) in many different parts of the body. Tumors may be either noncancerous or cancerous and most frequently appear during young adulthood; however, the signs and symptoms of von Hippel-Lindau syndrome can occur throughout life.

What are the causes of Von Hippel-Lindau (VHL) Syndrome?

Mutations in the VHL gene cause von Hippel-Lindau syndrome. The VHL gene is a tumor suppressor gene, which means it keeps cells from growing and dividing too rapidly or in an uncontrolled way. Mutations in this gene prevent production of the VHL protein or lead to the production of an abnormal version of the protein. An altered or missing VHL protein cannot effectively regulate cell survival and division. As a result, cells grow and divide uncontrollably to form the tumors and cysts that are characteristic of von Hippel-Lindau syndrome.

How prevalent is Von Hippel-Lindau (VHL) Syndrome?

The incidence of von Hippel-Lindau syndrome is estimated to be 1 in 36,000 individuals.

Is Von Hippel-Lindau (VHL) Syndrome an inherited disorder?

Mutations in the VHL gene are inherited in an autosomal dominant pattern, which means that one copy of the altered gene in each cell is sufficient to increase the risk of developing tumors and cysts. Most people with von Hippel-Lindau syndrome inherit an altered copy of the gene from an affected parent. In about 20 percent of cases, however, the altered gene is the result of a new mutation that occurred during the formation of reproductive cells (eggs or sperm) or very early in development.

Who are the top Von Hippel-Lindau (VHL) Syndrome Local Doctors?
Umberto Capitanio
Elite in Von Hippel-Lindau (VHL) Syndrome
Elite in Von Hippel-Lindau (VHL) Syndrome
Milan, IT 

Umberto Capitanio practices in Milan, Italy. Mr. Capitanio and is rated as an Elite expert by MediFind in the treatment of Von Hippel-Lindau (VHL) Syndrome. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Von Hippel-Lindau (VHL) Syndrome, Nephrectomy, and Prostatectomy.

Elite in Von Hippel-Lindau (VHL) Syndrome
Elite in Von Hippel-Lindau (VHL) Syndrome

Osu Internal Medicine LLC

3900 Stoneridge Ln, 
Dublin, OH 
Languages Spoken:
English
Accepting New Patients

Russell Lonser is a Neurosurgery provider in Dublin, Ohio. Dr. Lonser and is rated as an Elite provider by MediFind in the treatment of Von Hippel-Lindau (VHL) Syndrome. His top areas of expertise are Hemangioblastoma, Von Hippel-Lindau (VHL) Syndrome, Hemangioma, Awake Craniotomy, and Craniectomy. Dr. Lonser is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Von Hippel-Lindau (VHL) Syndrome
Elite in Von Hippel-Lindau (VHL) Syndrome
8 Xishiku Street, 
Beijing, CN 

Kan Gong practices in Beijing, China. Mr. Gong and is rated as an Elite expert by MediFind in the treatment of Von Hippel-Lindau (VHL) Syndrome. His top areas of expertise are Von Hippel-Lindau (VHL) Syndrome, Hemangioblastoma, Renal Cell Carcinoma (RCC), Nephrectomy, and Thrombectomy.

What are the latest Von Hippel-Lindau (VHL) Syndrome Clinical Trials?
NEI Intramural Biorepository for Retinal Diseases

Background: - To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time. They also want to study body tissues and blood to understand the nature of eye disease. Studying genes, cells, and tissues may help them understand why some people get eye problems and others do not, or why some peo...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations

Summary: This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterati...

Who are the sources who wrote this article ?

Published Date: October 01, 2018
Published By: National Institutes of Health